Think10

www.Think-10.com is a life science business consultancy, a personal coaching and team development to all businesses and a service to the pharmaceutical industry to facilitate change,

Melanie Lee PhD, CBE, FMedSci, DSc(Hons)

LifeArc

Chief Executive Officer

Principal CEO

BTGplc

BTG plc is a fast growing exciting Interventional Medicine company - on the international stage with it's HQ in London. We have device and drug combination products in the Interventional vascular and oncology space and have recently entered the Interventional Pulmonary area with the acquisition of PneuMRx and their innovative coiled device to treat emphysema patients. Interventional medicine routes to the market place in the hands of skilled physicians is likely to be relevant to many of the emerging new modalities in the pipelines of our innovative biotechs today.

Chief Scientific Officer

NightstaRx Ltd

NightstaRx is a Syncona backed company established to pursue the gene therapy treatment of Choroideremia to prevent the deterioration of eyesight in patients with this X-linked disease which causes loss of sight during the mid 40-50 years of life. Early clinical studies by Robert MacLaren have shown promising efficacy and good safety. The therapy for this indication is to replace the faulty REP1 gene in the eye with a functioning copy in an AAV vector. NightstaRx aims to gain regulatory approval for this therapy with ensuring GMP of the product and agreeing the pivotal clinical path. Www.nightstarx.co.uk

NED (was Founding CEO during 2014)

Syntaxin Ltd

Syntaxin was a successful biotech spun out of the HPA that was developed by myself and my management team, with the help if course of our excellent scientists, to a stage for acquisition to ensure the further investment in the recombinant botulinum toxin technology. Ipsen acquired Syntaxin in July 2013 and the site continues as Ipsen's centre for toxin engineering, complementing well the Ipsen expertise in toxin biology. I left Syntaxin with the acquisition and now work through Think10 as I discuss new opportunities.

Chief Executive officer

EVP and President UCB NewMedicines

Breast Cancer Haven

Angel

Applied Genomics Link Scheme

Working to award funds to innovate collaborative programmes between strong academic groups and small companies.

Chairman

Celltech

EVP R&D, Celltech

Glaxo

Unit Head

I'm a passionate leader dedicated to driving innovation and positive impact in the life sciences industry.🔬

Throughout my career, I have championed the translation of scientific knowledge into impactful healthcare solutions and am passionate about fostering an environment that encourages multidisciplinary collaboration, nurtures scientific talent, and supports the next generation of innovators.

I actively engage with industry leaders, policymakers, and research institutions to shape the future of the life sciences ecosystem.

By participating in conferences, thought leadership activities, and industry forums, I strive to drive positive change and advance the boundaries of medical research.

I am always excited to speak with like-minded professionals, researchers, and individuals passionate about making a difference in healthcare. ⬇️

Let's amplify our impact in healthcare by connecting and collaborating towards a brighter future.🧑🏻‍🔬

Melanie Lee

Accuray

As the Head of PMO & Global Business Excellence at Accuray, I lead a dynamic team dedicated to driving strategic initiatives and ensuring operational excellence across the organization. My role involves overseeing project management processes, optimizing business performance, and implementing best practices to enhance efficiency and effectiveness. My team collaborate cross-functionally to align projects with corporate goals, manage resources, and deliver high-impact results. By fostering a culture of continuous improvement and innovation, we play a pivotal role in advancing Accuray’s mission to improve patient outcomes through cutting-edge medical technology.

VP, Global Business Excellence & PMO

CamAlex Castle Consulting (Founder)

Providing expertise to the Biopharma and Med. Tech. industry with focused experience in research and development (R&D), translating strategy into operational success and sustainable growth.  Areas of expertise include:
Portfolio and Project Management | Strategic and Tactical Planning and Execution | Financial Operations | Clinical Operations | Resource Management |  Business Intelligence and Analytics |  Change Management | System Development | People and Space Planning | Team Building | Leadership, and Mentoring | Process Improvement

Bio-Pharma Consultant

Enzyvant

At Enzyvant I led a team of project managers across both development and commercial phase assets. I guided the creation, analysis and refinement of drug development and post-approval strategies for multiple programs at both the portfolio and project deliverable level. I brought unique expertise to identify the most efficient path to success with focus on performance and accountability to accelerate delivery against objectives with streamlined resources and the highest quality.

VP, Head of Program & Portfolio Management, Enzyvant

FlowMetric Life Sciences

Served on leadership team for niche Contract Research Organization with 50 employees globally.
Held accountable for P&L and ROI and for all aspects of global launch of a novel, patented global diagnostics platform. 
Developed strategic plan and secured funding from several investors in first 3 months. Launched within 6 months with best-in-class partners and vendors, platform website and digital portal to support e-commerce, robust supply chain and associated logistics. Expanded revenue streams and return on investment >10X through unique pathway and partnerships that further enhanced launch plan. Mapped successful regulatory path for multi-channel launch. Achieved revenues > $400M in first six months of launch. Left FlowMetric after it was purchased by KCAS and product was removed from portfolio.

Executive Vice President and General Manager of FlowMetric Life Sciences

Head of portfolio planning, R&D finance, systems and analytics. In this broad role I had accountability for R&D operations including leading the project management function and  ownership of the R&D annual budget incorporating financial management best practices and oversight. Specifically, I was accountable for the management of the overall R&D portfolio of projects including ensuring maintenance of the budget in line with agreed targets while ensuring delivery against R&D Corporate milestones. Since leading R&D finance R&D achieved an actual to budget full year variance of <5% for 3 consecutive years
In addition I was focused on developing the processes, systems and analytics to facilitate best in class portfolio management to maximize return on investment for the company. 
This was achieved by building upon strong Development practices and Commercial acumen to realize a robust pipeline of high value products for future growth across all areas of the company. 

Key Accomplishments include:
- introduced portfolio planning across entire project line including identification of portfolio value drivers in mid to long term 
- reduced R&D spend vs. budget variance from >10% to <2% in 3 three years
- revamped performance setting resulting in development milestone attainment improving 35% 
- centralized tracking and reporting of clinical studies across all business units

Senior Vice President and Head of Portfolio Planning, Systems & Analytics

Allergan

Site head of the Bridgewater Allergan R&D location with regional responsibility for all local Development operations. I was also head of Global R&D Resource Planning, Business Analytics and R&D Systems group within the Business Strategy Function.
Responsibilities include:
- Site Head; Bridgewater - R&D Allergan
- Regional Development Head of Operations with 14 direct and greater than 100 indirect reports
- Oversaw the R&D Portfolio Budget ($1B annual budget)
- Led clinical resource planning using objective resource analytics across clinical operations. 

Other experience at Allergan: Submitted >10 INDs including both small molecule and biologic entities. Project management background across all phases of Development including submission and post marketing commitments.

Sr. Director & Head - Business Analytics, Capacity Planning & Systems & Site Head of AGN Bridgewater

Responsible for both project management of two Development projects and leader of R&D metrics, productivity and clinical resource management

Director, Analysis Group; Global Project & Portfolio Management

Experienced life sciences senior leader with proven record of successful operational delivery and value creation. 

Focus: Leading strategy and operations including project & program management, portfolio optimization & planning, finance, clinical operations, capacity planning, productivity & performance management  

Ph.D. (immunology / pathogenic microbiology) trained professional with more than 20 years of biopharma, medical technology and diagnostics industry experience

taplio

The Battle

Melanie Lee

Grant Morgan

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?